LiPlasome Pharma A/S

LiPlasome Pharma is a biotechnology company, established in 2001.

LiPlasome is a Danish privately owned biotech company focusing on oncology.

The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like Cispaltin -> LiPlaCis® and Oxaliplatin -> LiPloxa.

The aim is to provide more effective treatment to cancer patients with fewer side effects.

LiPlasomes most advanced program I LiPlaCis® in a close escalating clinical phase I trial. In addition one programme is in pre-clinical development.

LiPlasome Pharma A/S
Dandyvej 19
DK-7100 Vejle

CEO
peter.buhl.jensen@vecata.com
Phone: +45 216 089 22

COO
mogens.winkel.madsen@vecata.com
Phone: +45 268 014 21